Beyond circadian rhythms: emerging roles of ultradian rhythms in control of liver functions

Gad Asher, Bokai Zhu – 18 May 2022 – The mammalian liver must cope with various metabolic and physiological changes that normally recur every day and primarily stem from daily cycles of rest‐activity and fasting‐feeding. Although a large body of evidence supports the reciprocal regulation of circadian rhythms and liver function, the research on the hepatic ultradian rhythms have largely been lagging behind.

Liver transplantation of partial grafts after ex situ splitting during hypothermic oxygenated perfusion—The HOPE–Split pilot study

Guillaume Rossignol, Xavier Muller, Valérie Hervieu, Sophie Collardeau‐Frachon, Antoine Breton, Natacha Boulanger, Mickaël Lesurtel, Rémi Dubois, Kayvan Mohkam, Jean‐Yves Mabrut – 17 May 2022 – Partial liver grafts from ex situ splitting are considered marginal due to prolonged static cold storage. The use of ex situ hypothermic oxygenated perfusion (HOPE) may offer a strategy to improve preservation of ex situ split grafts.

Impact of major hepatocellular carcinoma policy changes on liver transplantation for hepatocellular carcinoma in the United States

Rahil H. Shah, Darius Chyou, David S. Goldberg – 17 May 2022 – Since its inception in 2002, Model for End‐Stage Liver Disease (MELD)–based allocation has undergone a series of revisions, especially with respect to exception points. Hepatocellular carcinoma (HCC) is the most common indication for MELD exceptions, and as a result of higher transplant proportions and lower waitlist mortality, a series of policy changes have been implemented to deprioritize HCC transplants. We examined the impact of HCC exception policy changes on transplant and waitlist mortality rates.

Favorable impact of long‐term SGLT2 inhibitor for NAFLD complicated by diabetes mellitus: A 5‐year follow‐up study

Norio Akuta, Yusuke Kawamura, Shunichiro Fujiyama, Satoshi Saito, Nozomu Muraishi, Hitomi Sezaki, Tetsuya Hosaka, Masahiro Kobayashi, Mariko Kobayashi, Yasuji Arase, Kenji Ikeda, Fumitaka Suzuki, Yoshiyuki Suzuki, Hiromitsu Kumada – 16 May 2022 – The aim of this study was to determine the impact at 5 years of sodium‐glucose cotransporter 2 inhibitor (SGLT2i) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes mellitus (T2DM) on liver histopathology and clinical features.

Subscribe to